Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth

Magdalena Keller, Rosemarie Marchan|Journal of Experimental & Clinical Cancer Research|2023

Cited by 34